Prolonged n-3 polyunsaturated fatty acid supplementation ameliorates hepatic steatosis in patients with non-alcoholic fatty liver disease: A pilot study

M. Capanni, F. Calella, M. R. Biagini, S. Genise, L. Raimondi, G. Bedogni, G. Svegliati-Baroni, F. Sofi, S. Milani, R. Abbate, C. Surrenti, A. Casini

Research output: Contribution to journalArticle

Abstract

Background: Recent studies suggest a role of n-3 long-chain polyunsaturated fatty acids (n-3 PUFA) as peroxisome proliferator-activated receptor-α ligands in improving non-alcoholic fatty liver disease (NAFLD) in rodents. However, data in humans are still lacking. Aim: To evaluate the efficacy of prolonged PUFA supplementation in patients with NAFLD. Methods: Fifty-six patients with NAFLD were enrolled. Among the overall eligible patients, 42 assumed n-3 PUFA 1-g capsule daily for 12 months, whereas 14 refused the treatment and were analysed as controls. All patients underwent haematochemical and ultrasound follow-up. Results: Polyunsaturated fatty acid supplementation significantly decreased serum aspartate transaminase (P = 0.003), alanine transaminase (P = 0.002), γ-glutamyl transpeptidase (P = 0.03), triglycerides (P = 0.02) and fasting glucose (P = 0.02) in comparison with controls. Circulating arachidonate and n-6/n-3 fatty acid ratio was reduced (P = 0.0002, and P = 0.0001 respectively) in treated patients. Moreover, ultrasonography demonstrated improvement of liver echotexture after PUFA (P = 0.0001), and increase of Doppler perfusion index (P = 0.001), whereas no significant changes occurred in controls. Conclusions: Supplementation with n-3 PUFA improves biochemical, ultrasonographic and haemodynamic features of liver steatosis. Our study supports the efficacy of n-3 PUFA as a new therapeutic approach in the treatment of NAFLD.

Original languageEnglish
Pages (from-to)1143-1151
Number of pages9
JournalAlimentary Pharmacology and Therapeutics
Volume23
Issue number8
DOIs
Publication statusPublished - Apr 2006

Fingerprint

Omega-3 Fatty Acids
Unsaturated Fatty Acids
Liver
Peroxisome Proliferator-Activated Receptors
gamma-Glutamyltransferase
Fatty Liver
Aspartate Aminotransferases
Alanine Transaminase
Capsules
Rodentia
Fasting
Ultrasonography
Triglycerides
Therapeutics
Perfusion
Hemodynamics
Non-alcoholic Fatty Liver Disease
Ligands
Glucose
Serum

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Prolonged n-3 polyunsaturated fatty acid supplementation ameliorates hepatic steatosis in patients with non-alcoholic fatty liver disease : A pilot study. / Capanni, M.; Calella, F.; Biagini, M. R.; Genise, S.; Raimondi, L.; Bedogni, G.; Svegliati-Baroni, G.; Sofi, F.; Milani, S.; Abbate, R.; Surrenti, C.; Casini, A.

In: Alimentary Pharmacology and Therapeutics, Vol. 23, No. 8, 04.2006, p. 1143-1151.

Research output: Contribution to journalArticle

Capanni, M, Calella, F, Biagini, MR, Genise, S, Raimondi, L, Bedogni, G, Svegliati-Baroni, G, Sofi, F, Milani, S, Abbate, R, Surrenti, C & Casini, A 2006, 'Prolonged n-3 polyunsaturated fatty acid supplementation ameliorates hepatic steatosis in patients with non-alcoholic fatty liver disease: A pilot study', Alimentary Pharmacology and Therapeutics, vol. 23, no. 8, pp. 1143-1151. https://doi.org/10.1111/j.1365-2036.2006.02885.x
Capanni, M. ; Calella, F. ; Biagini, M. R. ; Genise, S. ; Raimondi, L. ; Bedogni, G. ; Svegliati-Baroni, G. ; Sofi, F. ; Milani, S. ; Abbate, R. ; Surrenti, C. ; Casini, A. / Prolonged n-3 polyunsaturated fatty acid supplementation ameliorates hepatic steatosis in patients with non-alcoholic fatty liver disease : A pilot study. In: Alimentary Pharmacology and Therapeutics. 2006 ; Vol. 23, No. 8. pp. 1143-1151.
@article{b09182d349eb4fc8bc8e24ddcc56ebda,
title = "Prolonged n-3 polyunsaturated fatty acid supplementation ameliorates hepatic steatosis in patients with non-alcoholic fatty liver disease: A pilot study",
abstract = "Background: Recent studies suggest a role of n-3 long-chain polyunsaturated fatty acids (n-3 PUFA) as peroxisome proliferator-activated receptor-α ligands in improving non-alcoholic fatty liver disease (NAFLD) in rodents. However, data in humans are still lacking. Aim: To evaluate the efficacy of prolonged PUFA supplementation in patients with NAFLD. Methods: Fifty-six patients with NAFLD were enrolled. Among the overall eligible patients, 42 assumed n-3 PUFA 1-g capsule daily for 12 months, whereas 14 refused the treatment and were analysed as controls. All patients underwent haematochemical and ultrasound follow-up. Results: Polyunsaturated fatty acid supplementation significantly decreased serum aspartate transaminase (P = 0.003), alanine transaminase (P = 0.002), γ-glutamyl transpeptidase (P = 0.03), triglycerides (P = 0.02) and fasting glucose (P = 0.02) in comparison with controls. Circulating arachidonate and n-6/n-3 fatty acid ratio was reduced (P = 0.0002, and P = 0.0001 respectively) in treated patients. Moreover, ultrasonography demonstrated improvement of liver echotexture after PUFA (P = 0.0001), and increase of Doppler perfusion index (P = 0.001), whereas no significant changes occurred in controls. Conclusions: Supplementation with n-3 PUFA improves biochemical, ultrasonographic and haemodynamic features of liver steatosis. Our study supports the efficacy of n-3 PUFA as a new therapeutic approach in the treatment of NAFLD.",
author = "M. Capanni and F. Calella and Biagini, {M. R.} and S. Genise and L. Raimondi and G. Bedogni and G. Svegliati-Baroni and F. Sofi and S. Milani and R. Abbate and C. Surrenti and A. Casini",
year = "2006",
month = "4",
doi = "10.1111/j.1365-2036.2006.02885.x",
language = "English",
volume = "23",
pages = "1143--1151",
journal = "Alimentary Pharmacology and Therapeutics",
issn = "0269-2813",
publisher = "Wiley-Blackwell Publishing Ltd",
number = "8",

}

TY - JOUR

T1 - Prolonged n-3 polyunsaturated fatty acid supplementation ameliorates hepatic steatosis in patients with non-alcoholic fatty liver disease

T2 - A pilot study

AU - Capanni, M.

AU - Calella, F.

AU - Biagini, M. R.

AU - Genise, S.

AU - Raimondi, L.

AU - Bedogni, G.

AU - Svegliati-Baroni, G.

AU - Sofi, F.

AU - Milani, S.

AU - Abbate, R.

AU - Surrenti, C.

AU - Casini, A.

PY - 2006/4

Y1 - 2006/4

N2 - Background: Recent studies suggest a role of n-3 long-chain polyunsaturated fatty acids (n-3 PUFA) as peroxisome proliferator-activated receptor-α ligands in improving non-alcoholic fatty liver disease (NAFLD) in rodents. However, data in humans are still lacking. Aim: To evaluate the efficacy of prolonged PUFA supplementation in patients with NAFLD. Methods: Fifty-six patients with NAFLD were enrolled. Among the overall eligible patients, 42 assumed n-3 PUFA 1-g capsule daily for 12 months, whereas 14 refused the treatment and were analysed as controls. All patients underwent haematochemical and ultrasound follow-up. Results: Polyunsaturated fatty acid supplementation significantly decreased serum aspartate transaminase (P = 0.003), alanine transaminase (P = 0.002), γ-glutamyl transpeptidase (P = 0.03), triglycerides (P = 0.02) and fasting glucose (P = 0.02) in comparison with controls. Circulating arachidonate and n-6/n-3 fatty acid ratio was reduced (P = 0.0002, and P = 0.0001 respectively) in treated patients. Moreover, ultrasonography demonstrated improvement of liver echotexture after PUFA (P = 0.0001), and increase of Doppler perfusion index (P = 0.001), whereas no significant changes occurred in controls. Conclusions: Supplementation with n-3 PUFA improves biochemical, ultrasonographic and haemodynamic features of liver steatosis. Our study supports the efficacy of n-3 PUFA as a new therapeutic approach in the treatment of NAFLD.

AB - Background: Recent studies suggest a role of n-3 long-chain polyunsaturated fatty acids (n-3 PUFA) as peroxisome proliferator-activated receptor-α ligands in improving non-alcoholic fatty liver disease (NAFLD) in rodents. However, data in humans are still lacking. Aim: To evaluate the efficacy of prolonged PUFA supplementation in patients with NAFLD. Methods: Fifty-six patients with NAFLD were enrolled. Among the overall eligible patients, 42 assumed n-3 PUFA 1-g capsule daily for 12 months, whereas 14 refused the treatment and were analysed as controls. All patients underwent haematochemical and ultrasound follow-up. Results: Polyunsaturated fatty acid supplementation significantly decreased serum aspartate transaminase (P = 0.003), alanine transaminase (P = 0.002), γ-glutamyl transpeptidase (P = 0.03), triglycerides (P = 0.02) and fasting glucose (P = 0.02) in comparison with controls. Circulating arachidonate and n-6/n-3 fatty acid ratio was reduced (P = 0.0002, and P = 0.0001 respectively) in treated patients. Moreover, ultrasonography demonstrated improvement of liver echotexture after PUFA (P = 0.0001), and increase of Doppler perfusion index (P = 0.001), whereas no significant changes occurred in controls. Conclusions: Supplementation with n-3 PUFA improves biochemical, ultrasonographic and haemodynamic features of liver steatosis. Our study supports the efficacy of n-3 PUFA as a new therapeutic approach in the treatment of NAFLD.

UR - http://www.scopus.com/inward/record.url?scp=33646882162&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33646882162&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2036.2006.02885.x

DO - 10.1111/j.1365-2036.2006.02885.x

M3 - Article

C2 - 16611275

AN - SCOPUS:33646882162

VL - 23

SP - 1143

EP - 1151

JO - Alimentary Pharmacology and Therapeutics

JF - Alimentary Pharmacology and Therapeutics

SN - 0269-2813

IS - 8

ER -